C Ostheimer1, C Evers1, F Palm1,2, R Mikolajczyk2, D Vordermark1, Daniel Medenwald3,4. 1. Department of Radiation Oncology, Martin Luther University, Halle, Germany. 2. Institute of Medical Epidemiology, Biometry and Informatics, Martin Luther University Halle-Wittenberg, Magdeburger Strasse 24, 06114, Halle (Saale), Germany. 3. Department of Radiation Oncology, Martin Luther University, Halle, Germany. Daniel.Medenwald@uk-halle.de. 4. Institute of Medical Epidemiology, Biometry and Informatics, Martin Luther University Halle-Wittenberg, Magdeburger Strasse 24, 06114, Halle (Saale), Germany. Daniel.Medenwald@uk-halle.de.
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) can achieve high tumour control with limited toxicity for inoperable early stage non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: The German Epidemiologic Cancer Registries from the Robert-Koch Institute were assessed. Periods according to the availability of SBRT were: (1) 2000-2003 (pre-SBRT); (2) 2004-2007 (interim); and (3) 2007-2014 (broad availability of SBRT). To assess the association of cancer-related parameters with mortality, hazard ratios (HR) from Cox proportional hazards models were computed. To evaluate the change of treatment-related mortality, we performed interaction analyses and the relative excess risk due to interaction (RERI, additive scale) was computed. RESULTS: A total of 16,292 patients with UICC stage I NSCLC diagnosed between 2000 and 2014 were analysed. Radiotherapy utilization increased from 5% in pre-SBRT era to 8.8% after 2007. In univariate analyses, survival in the whole cohort improved only marginally when 2000-2003 is compared to 2004-2007 (HR 0.92, 95% CI 0.85-1.01) or 2008-2014 (HR 0.93, 95% CI 0.86-1.01). Comparing surgery/radiotherapy, mortality in the radiotherapy group started from a 3.5-fold risk in 2000-2003 to 2.6 after 2007. The interaction analysis revealed a stronger improvement for radiotherapy (multiplicative scale for 2000-2003 vs. > 2007: 0.74, 95% CI 0.58-0.94). On an additive scale, treatment × period interaction revealed an RERI for 2000-2003 vs. > 2007 of - 1.18 (95% CI - 1.8, - 0.55). CONCLUSIONS: Using population-based data, we observed a survival improvement in stage I lung cancer over time. With an increasing utilization of radiotherapy, a stronger improvement occurred in patients treated with radiotherapy when compared to surgery.
BACKGROUND: Stereotactic body radiotherapy (SBRT) can achieve high tumour control with limited toxicity for inoperable early stage non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: The German Epidemiologic Cancer Registries from the Robert-Koch Institute were assessed. Periods according to the availability of SBRT were: (1) 2000-2003 (pre-SBRT); (2) 2004-2007 (interim); and (3) 2007-2014 (broad availability of SBRT). To assess the association of cancer-related parameters with mortality, hazard ratios (HR) from Cox proportional hazards models were computed. To evaluate the change of treatment-related mortality, we performed interaction analyses and the relative excess risk due to interaction (RERI, additive scale) was computed. RESULTS: A total of 16,292 patients with UICC stage I NSCLC diagnosed between 2000 and 2014 were analysed. Radiotherapy utilization increased from 5% in pre-SBRT era to 8.8% after 2007. In univariate analyses, survival in the whole cohort improved only marginally when 2000-2003 is compared to 2004-2007 (HR 0.92, 95% CI 0.85-1.01) or 2008-2014 (HR 0.93, 95% CI 0.86-1.01). Comparing surgery/radiotherapy, mortality in the radiotherapy group started from a 3.5-fold risk in 2000-2003 to 2.6 after 2007. The interaction analysis revealed a stronger improvement for radiotherapy (multiplicative scale for 2000-2003 vs. > 2007: 0.74, 95% CI 0.58-0.94). On an additive scale, treatment × period interaction revealed an RERI for 2000-2003 vs. > 2007 of - 1.18 (95% CI - 1.8, - 0.55). CONCLUSIONS: Using population-based data, we observed a survival improvement in stage I lung cancer over time. With an increasing utilization of radiotherapy, a stronger improvement occurred in patients treated with radiotherapy when compared to surgery.
Entities:
Keywords:
Lung cancer; Non-small-cell lung cancer; Patterns of care; Population-based analysis; Radiotherapy; Stage I; Stereotactic body radiotherapy
Authors: Benjamin Hager; Klaus Kraywinkel; Bastian Keck; Alexander Katalinic; Martin Meyer; Sylke Ruth Zeissig; Roland Stabenow; Michael Froehner; Johannes Huber Journal: Radiother Oncol Date: 2015-03-11 Impact factor: 6.280
Authors: Andrea Eberle; Lina Jansen; Felipe Castro; Agne Krilaviciute; Sabine Luttmann; Katharina Emrich; Bernd Holleczek; Alice Nennecke; Alexander Katalinic; Hermann Brenner Journal: Lung Cancer Date: 2015-10-20 Impact factor: 5.705
Authors: Mirjam J Knol; Tyler J VanderWeele; Rolf H H Groenwold; Olaf H Klungel; Maroeska M Rovers; Diederick E Grobbee Journal: Eur J Epidemiol Date: 2011-02-23 Impact factor: 8.082
Authors: Miep A van der Drift; Henrike E Karim-Kos; Sabine Siesling; Harry J M Groen; Michel W J M Wouters; Jan-Willem Coebergh; Esther de Vries; Maryska L G Janssen-Heijnen Journal: J Thorac Oncol Date: 2012-02 Impact factor: 15.609
Authors: Samuel Cykert; Peggye Dilworth-Anderson; Michael H Monroe; Paul Walker; Franklin R McGuire; Giselle Corbie-Smith; Lloyd J Edwards; Audrina Jones Bunton Journal: JAMA Date: 2010-06-16 Impact factor: 56.272
Authors: Michael T Vest; Jeph Herrin; Pamela R Soulos; Roy H Decker; Lynn Tanoue; Gaetane Michaud; Anthony W Kim; Frank Detterbeck; Daniel Morgensztern; Cary P Gross Journal: Chest Date: 2013-02-01 Impact factor: 9.410
Authors: Rhami Khorfan; Timothy J Kruser; Julia M Coughlin; Ankit Bharat; Karl Y Bilimoria; David D Odell Journal: Ann Thorac Surg Date: 2020-03-05 Impact factor: 4.330
Authors: Nicholas R Mayne; Belle K Lin; Alice J Darling; Vignesh Raman; Deven C Patel; Douglas Z Liou; Thomas A D'Amico; Chi-Fu Jeffrey Yang Journal: Ann Surg Date: 2020-12 Impact factor: 13.787